Get the Stockscreener App
1.21
15.38%
-0.22
Pre-market:
1.12
-0.09
-7.44%
Plus Therapeutics Inc stock is traded at $1.21, with a volume of 2.98M.
It is down -15.38% in the last 24 hours and up +8.04% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$1.43
Open:
$1.41
24h Volume:
2.98M
Relative Volume:
0.40
Market Cap:
$7.13M
Revenue:
-
Net Income/Loss:
$-12.89M
P/E Ratio:
-0.4783
EPS:
-2.53
Net Cash Flow:
$-11.95M
1W Performance:
+245.71%
1M Performance:
+8.04%
6M Performance:
-15.38%
1Y Performance:
-31.64%
1-Day Range:
$1.16
$1.47
1-Week Range:
$0.4662
$2.3099
52-Week Range:
$0.284
$2.6702
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
1.21 | 7.13M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement - Bluefield Daily Telegraph
Plus Therapeutics Raises $15M: Strategic Financial Move Includes Debt Conversion - StockTitan
Plus Therapeutics Regains Nasdaq Compliance - Nasdaq
Plus Therapeutics regains Nasdaq compliance status By Investing.com - Investing.com Australia
Plus Therapeutics regains Nasdaq compliance - Investing.com India
SEC Form 424B3 filed by PLUS THERAPEUTICS Inc. - Quantisnow
Plus Therapeutics Regains Compliance With Nasdaq Minimum Stockholders' Equity Requirement - Marketscreener.com
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement - GlobeNewswire
Plus Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement - Nasdaq
Plus Therapeutics regains Nasdaq compliance status - Investing.com
PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy - MSN
Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday - Insider Monkey
Plus Therapeutics Announces Peer-Reviewed Publication in - GlobeNewswire
Plus Therapeutics Continues Rally On FridayHere's Why - Benzinga
Plus Therapeutics' Brain Cancer Therapy Shows Promise in Early-Stage Study; Shares Rise - Marketscreener.com
Pre-Hour Momentum Drives Plus Therapeutics (PSTV) Stock Higher On FDA Designation - Stocks Telegraph
FDA ODD given to Plus Therapeutics’ injectable radiotherapy - Yahoo Finance
Breakthrough Brain Cancer Treatment Doubles Patient Survival: Phase 1 Results Revealed - StockTitan
RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial - Nature.com
Plus Therapeutics’ $15 Million Private Placement - Global Legal Chronicle
Pharma Stock Plus Therapeutics, Inc. (Nasdaq: $PSTV) Makes NASDAQ Top Gainer List on FDA News - Investorideas.com newswire
Plus Therapeutics soars on FDA Orphan Drug Designation for lung cancer treatment - MSN
Plus Therapeutics Gets FDA Orphan Drug Designation for Rhenium Obisbemeda in Lung Cancer; Shares Surge - Marketscreener.com
Plus Therapeutics stock rises on FDA Orphan tag (PSTV:NASDAQ) - Seeking Alpha
FDA grants orphan drug status to Plus Therapeutics’ cancer treatment By Investing.com - Investing.com South Africa
FDA grants orphan drug status to Plus Therapeutics’ cancer treatment - Investing.com
Plus Therapeutics secures $5.7M to support leptomeningeal metastases program - MSN
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation For Rhenium (186Re) Obisbemeda - Marketscreener.com
Plus Therapeutics granted Orphan Drug Designation for Rhenium Obisbemeda - TipRanks
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation - GlobeNewswire
Can This Rare FDA Designation Transform Plus Therapeutics' Cancer Treatment Future? - StockTitan
Plus Therapeutics Announces New Employment Inducement Grants - The Manila Times
Plus Therapeutics Awards 30,000 Stock Options to Newly Appointed CDOWhat's the Vesting Timeline? - StockTitan
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds - GlobeNewswire
Plus Therapeutics Expects $15 Million in Gross Proceeds From Private Placement of Units; Shares Fall - Marketscreener.com
Plus Therapeutics tumbles on $15M private placement - MSN
Plus Therapeutics sees $15M in gross proceeds from private placement - TipRanks
Plus Therapeutics, Inc. Announces $15 Million Private Placement to Advance CNS Cancer Therapies - Nasdaq
Can Plus Therapeutics' $15M Financing Solve Its Nasdaq Delisting Challenge? - StockTitan
Leptomeningeal Metastases Market Anticipated to Expand - openPR
Understanding the Risks of Investing in Plus Therapeutics Inc (PSTV) - Knox Daily
Glioma Treatment Market Size Report 2034 | AnHeart Therapeutics - openPR
Plus Therapeutics (PSTV) Projected to Post Quarterly Earnings on Tuesday - Defense World
Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Plus Therapeutics, Inc. Advances Lead Drug Rhenium Obisbemeda for Patients with Leptomeningeal Metastases - Marketscreener.com
Plus Therapeutics sets dose for CNS cancer treatment trial By Investing.com - Investing.com Canada
Plus Therapeutics sets dose for CNS cancer treatment trial - Investing.com India
Plus Therapeutics Completes ReSPECT-LM Phase 1 Trial, Establishes RP2D for Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases - Nasdaq
Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with ... - The Bakersfield Californian
Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases - GlobeNewswire
Cancer Breakthrough? Plus Therapeutics' Drug Shows Complete Response in Difficult-to-Treat Brain Cancer Patient - StockTitan
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):